0
16. 5. 2024.
Increased incidence of co-trimoxazole induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors.
Our cross-sectional study demonstrates that there is a high rate of co-trimoxazole induced drug rash, in patients treated for immune related adverse events, with those developing rash appearing to have a reduced survival.